Skip to main navigation
Vaxcyte
  • Mission
  • Pipeline
  • Approach
  • About Us
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Tax Disclosures
  • Careers
Select Page
  • RSS Feeds
  • Email Alerts
  • IR Contact

Press Releases

Jun 01, 2023

Vaxcyte to Present at the Jefferies Healthcare Conference

May 08, 2023

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

May 03, 2023

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

Apr 21, 2023

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 19, 2023

Vaxcyte Announces Pricing of $500 Million Public Offering

Apr 17, 2023

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Apr 17, 2023

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

Apr 16, 2023

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

Mar 30, 2023

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Feb 27, 2023

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 14
Vaxcyte

ABOUT US

  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board

OUR PROGRAMS

  • High-Fidelity Vaccines Engineered to Go the Distance
  • The Rising Consequences of Bacterial Infections
  • Vaccine Candidates Engineered to Overtake Convention
  • Posters / Publications

INVESTORS & MEDIA

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor Resources
© 2023 Vaxcyte, Inc.
© 2023 Vaxcyte, Inc.